Kai Joachim Borm1, Markus Oechsner2, Mathias Düsberg3, Gabriel Buschner4, Wolfgang Weber5, Stephanie Elisabeth Combs6, Marciana-Nona Duma7. 1. Technical University Munich, Medical School, Klinikum rechts der Isar, Department of Radiation Oncology, Technical University of Munich (TUM), Germany. Electronic address: Kai.Borm@mri.tum.de. 2. Technical University Munich, Medical School, Klinikum rechts der Isar, Department of Radiation Oncology, Technical University of Munich (TUM), Germany. Electronic address: Markus.Oechsner@mri.tum.de. 3. Technical University Munich, Medical School, Klinikum rechts der Isar, Department of Radiation Oncology, Technical University of Munich (TUM), Germany. Electronic address: Mathias.Duesberg@mri.tum.de. 4. Technical University Munich, Medical School, Klinikum rechts der Isar, Department of Nuclear Medicine, Technical University of Munich (TUM), Germany. Electronic address: Gabriel.Buschner@mri.tum.de. 5. Technical University Munich, Medical School, Klinikum rechts der Isar, Department of Nuclear Medicine, Technical University of Munich (TUM), Germany. Electronic address: Wolfgang.Weber@mri.tum.de. 6. Technical University Munich, Medical School, Klinikum rechts der Isar, Department of Radiation Oncology, Technical University of Munich (TUM), Germany; Deutsches Konsortium für Translationale Krebsforschung (DKTK)-Partner Site Munich, Germany; Institute of Radiation Medicine, Helmholtzzentrum München, Neuherberg, Germany. Electronic address: Stephanie.Combs@tum.de. 7. Technical University Munich, Medical School, Klinikum rechts der Isar, Department of Radiation Oncology, Technical University of Munich (TUM), Germany; Department of Radiotherapy and Radiation Oncology, Friedrich Schiller University Hospital, Jena, Germany. Electronic address: Marciana-Nona.Duma@med.uni-jena.de.
Abstract
OBJECTIVE: The purpose of this study was to estimate the dose distribution from randomized trials (MA.20, EORTC 22922-10925 (EORTC), AMAROS and the Z0011 trial) on lymph node (LN) irradiation on a large LN atlas. METHODS: 580 F18-FDG-PET/CT positive LN metastases of 235 patients were transferred rigidly and non-rigidly to three "template CTs" (standard, obese and slender patient). Further, the LN clinical target volumes (CTVs) were contoured according to the ESTRO-guidelines. Treatment plans were designed (each for the left and right side) for all patients based on the study protocols of the MA.20, EORTC, AMAROS and Z0011 trial. Subsequently, the dose distribution in the ESTRO-CTVs and in the 580 LNs were assessed. RESULTS: Our results reveal variable dose coverage (26.8 ± 17.3 Gy-53.0 ± 1.8 Gy) in the targeted LN areas (ESTRO-CTV and LN) in dependence of the treatment planning design and the patients' body shape. None of the treatment plan designs provided full dose coverage to the lymphatic drainage system. High tangent irradiation resulted in a similar dose distribution in L I and II compared to the AMAROS field design. CONCLUSION: Inclusion of the entire lymphatic system may not be necessary for all patients to reproduce the oncologic benefit shown in the randomized LN-irradiation trials. Inclusion of axillary level II and extension of the supraclavicular CTV can be considered in selected high-risk patients, based on dose recalculation of the MA.20 trial. Further, our results amplify earlier assumptions that irradiation may have accounted for the good results after SLND alone in the Z0011 trial.
OBJECTIVE: The purpose of this study was to estimate the dose distribution from randomized trials (MA.20, EORTC 22922-10925 (EORTC), AMAROS and the Z0011 trial) on lymph node (LN) irradiation on a large LN atlas. METHODS: 580 F18-FDG-PET/CT positive LN metastases of 235 patients were transferred rigidly and non-rigidly to three "template CTs" (standard, obese and slender patient). Further, the LN clinical target volumes (CTVs) were contoured according to the ESTRO-guidelines. Treatment plans were designed (each for the left and right side) for all patients based on the study protocols of the MA.20, EORTC, AMAROS and Z0011 trial. Subsequently, the dose distribution in the ESTRO-CTVs and in the 580 LNs were assessed. RESULTS: Our results reveal variable dose coverage (26.8 ± 17.3 Gy-53.0 ± 1.8 Gy) in the targeted LN areas (ESTRO-CTV and LN) in dependence of the treatment planning design and the patients' body shape. None of the treatment plan designs provided full dose coverage to the lymphatic drainage system. High tangent irradiation resulted in a similar dose distribution in L I and II compared to the AMAROS field design. CONCLUSION: Inclusion of the entire lymphatic system may not be necessary for all patients to reproduce the oncologic benefit shown in the randomized LN-irradiation trials. Inclusion of axillary level II and extension of the supraclavicular CTV can be considered in selected high-risk patients, based on dose recalculation of the MA.20 trial. Further, our results amplify earlier assumptions that irradiation may have accounted for the good results after SLND alone in the Z0011 trial.
Authors: K J Borm; K Kessel; M Devecka; S Muench; C Straube; K Schiller; L Schüttrumpf; H Dapper; B Wöller; S Pigorsch; S E Combs Journal: Strahlenther Onkol Date: 2019-11-13 Impact factor: 3.621
Authors: Timothy D Malouff; Laura A Vallow; Wilza L Magalhaes; Danushka S Seneviratne; Mark R Waddle; Katherine S Tzou Journal: Cureus Date: 2022-03-29
Authors: Pieter Deseyne; Bruno Speleers; Leen Paelinck; Werner De Gersem; Wilfried De Neve; Max Schoepen; Annick Van Greveling; Hans Van Hulle; Vincent Vakaet; Giselle Post; Chris Monten; Herman Depypere; Liv Veldeman Journal: Sci Rep Date: 2022-02-03 Impact factor: 4.379